Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 838-850

  Fenoglio, Daniela ^a,b,c   Parodi, Alessia ^a   Lavieri, Rosa ^a   Kalli, Francesca ^a   Ferrera, Francesca ^a   Tagliamacco, Augusto ^b   Guastalla, Andrea ^a,b   Lamperti, Maria Giuseppina ^d   Giacomini, Mauro ^a   Filaci, Gilberto ^a,b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Mediolanum Farmaceutici SpA   (Italy)

Author keywords

Cancer vaccines; Cytokine intracellular staining; Elispot; GX301; Immunogenicity; Telomerase

Indexed keywords

CANCER VACCINE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; GX301 VACCINE; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; TELOMERASE; UNCLASSIFIED DRUG; PEPTIDE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL LINE; VACCINATION; CLINICAL TRIAL; GENE; IMMUNOLOGY; METABOLISM;

ADULT; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENES, MHC CLASS I; HLA-A2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDES; TELOMERASE;

EID: 84938952627     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1012032     Document Type: Article

References (42)

1. Blackburn EH. Structure and function of telomeres. Nature 1991; 350:569-73; PMID:1708110; http://dx. doi. org/10. 1038/350569a0
2. Greider CW. Mammalian telomere dynamics: healing, fragmentation shortening and stabilization. Curr Opin Genet Dev 1994; 4:203-11; PMID:8032197; http:// dx. doi. org/10. 1016/S0959-437X(05)80046-2
3. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998; 12:1073-185; PMID:9553037; http://dx. doi. org/10. 1101/gad. 12. 8. 1073
4. Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF. Telomere structure and telomerase in health and disease (Review). Int J Oncol 2012; 41:1561-69; PMID:22941386
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-13; PMID:7605428; http://dx. doi. org/ 10. 1126/science. 7605428
6. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-68; PMID:10440377; http://dx. doi. org/10. 1038/22780
7. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an up-date. Virchows Arch 2000; 437:1-16; PMID:10963374; http://dx. doi. org/ 10. 1007/s004280000189
8. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10:673-79; PMID:10403642; http://dx. doi. org/10. 1016/S1074- 7613(00)80066-7
9. Minev B, Hipp J, Firat H, Schmidt JD, Langlade- Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci 2000; 97:4796-801; PMID:10759561; http://dx. doi. org/10. 1073/ pnas. 070560797
10. Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli AR, Basso M, et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 2006; 107:1505-12; PMID:16249379; http://dx. doi. org/10. 1182/blood-2005-01-0258
11. Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7:881-87; PMID:18767939; http://dx. doi. org/ 10. 1586/14760584. 7. 7. 881
12. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847-57
13. Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60:1553-64; PMID:21681371; http://dx. doi. org/10. 1007/s00262- 011-1061-z
14. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011; 19:990-99; PMID:21189474; http://dx. doi. org/10. 1038/ mt. 2010. 289
15. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008; 31:771-80; PMID:18779742; http://dx. doi. org/ 10. 1097/CJI. 0b013e3181833818
16. Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007; 5:12; PMID:17324292; http://dx. doi. org/10. 1186/ 1479-5876-5-12
17. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55:1553-64; PMID:16491401; http://dx. doi. org/ 10. 1007/s00262-006-0145-7
18. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. hTERT:540-548 peptide induces peptide- reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10:4688-98; PMID:15269141; http:// dx. doi. org/10. 1158/1078-0432. CCR-04-0325
19. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNAtransfected dendritic cells. Cancer Res 2003; 63:2127- 33; PMID:12727829
20. Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001; 61:8366-70; PMID:11731409
21. Ayyoub M, Migliaccio M, Guillaume P, Liénard D, Cerottini JC, Romero P, Lévy F, Speiser DE, Valmori D. Lack of tumor recognition by hTERT peptide 540- 548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol. 2001; 31:2642-51; PMID:11536162; http://dx. doi. org/10. 1002/1521-4141(200109)31:9%3c2642::AIDIMMU2642% 3e3. 0. CO;2-6
22. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx. doi. org/10. 1158/1078- 0432. CCR-09-0737
23. Fenoglio D, Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, Battaglia F, Ferrera F, Sciallero S, Murdaca G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 2013; 62:1041-52; PMID:23591981; http://dx. doi. org/10. 1007/s00262-013-1415-9
24. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-Helper cells. Cancer Res 2002; 62:2600-05; PMID:11980655
25. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 2003; 9:4743-55; PMID:14581345
26. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588-94; PMID:9794842; http://dx. doi. org/ 10. 1016/S0952-7915(98)80228-8
27. Young NT, Mulder A, Cerundolo V, Claas FH, Welsh KI. Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines. Tissue Antigens 1998; 52:368-73; PMID:9820600; http://dx. doi. org/10. 1111/j. 1399- 0039. 1998. tb03057. x
28. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCap model of human prostatic carcinoma. Cancer Res 1983; 43:1809-18; PMID:6831420
29. Manca F, Fenoglio D, Valle MT, Li Pira G, Kunkl A, Balderas RS, Baccala RG, Kono DH, Ferraris A, Saverino D, et al. Human T helper cells specific for HIV reverse transcriptase: possible role in intrastructural help for HIV envelope-specific antibodies. Eur J Immunol 1995; 25:1217-23; PMID:7539750; http://dx. doi. org/10. 1002/eji. 1830250513
30. Zheng X, Gao JX, Zhang H, Geiger TL, Liu Y, Zheng P. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 2002; 169:4761-69; PMID: 12391185; http://dx. doi. org/10. 4049/jimmunol. 169. 9. 4761
31. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 2006; 3:1-11; PMID:16549043
32. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178:27-47; PMID:8315383; http:// dx. doi. org/10. 1084/jem. 178. 1. 27
33. Maverakis E, van den Elzen P, Sercarz EE. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. J Autoimmun 2001; 16:201-9; PMID:11334484; http://dx. doi. org/10. 1006/ jaut. 2000. 0493
34. Sercarz EE, Maverakis E. Recognition and function in a degenerate immune system. Mol Immunol 2004; 40:1003-8; PMID:15036903; http://dx. doi. org/ 10. 1016/j. molimm. 2003. 11. 002
35. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013; 104:15-21; PMID:23107418; http://dx. doi. org/ 10. 1111/cas. 12050
36. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006; 12:2346s-52s; PMID:16609057; http://dx. doi. org/10. 1158/1078- 0432. CCR-05-2540
37. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for analysis of the HLA system. Immunol Rev 1979; 47:3-61; PMID:95015; http://dx. doi. org/10. 1111/j. 1600- 065X. 1979. tb00288. x
38. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57:303-15; PMID:17721781; http://dx. doi. org/ 10. 1007/s00262-007-0380-6
39. Calarota S A, Baldanti F. Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin Dev Immunol 2013; 2013:637649; PMID:24319467; http://dx. doi. org/ 10. 1155/2013/637649
40. Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, et al. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 2010; 5:e14330; PMID:21179404; http://dx. doi. org/ 10. 1371/journal. pone. 0014330
41. Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH. Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother 2012; 61:967-78; PMID:22714399; http://dx. doi. org/ 10. 1007/s00262-012-1282-9
42. Lavieri R, Filaci G, Fenoglio D, Giacomini M. ImmunoDB: a web based tool to analyze preclinical data. Stud Health Technol Inform 2014; 205:438-42; PMID:25160222